Tharimmune

THARPhase 2

Tharimmune is pioneering a transmucosal drug delivery platform designed to enhance the bioavailability and tolerability of challenging therapeutics. Its most advanced program, TH104, is in Phase 2 development for pruritus associated with PBC, a condition with no FDA-approved therapies. The company's strategy involves repurposing established drug molecules with its buccal film technology to create new, patent-protected treatments for serious conditions, aiming to accelerate development timelines and reduce risk.

Market Cap

$131.4M

Employees

1-10

Focus

Biotech

THAR · Stock Price

USD 3.33551.67 (-99.40%)

Historical price data

AI Company Overview

Technology Platform

A proprietary transmucosal buccal film drug delivery platform designed to enhance the systemic bioavailability and tolerability of therapeutics by administering them through the mucosal lining inside the cheek, bypassing first-pass liver metabolism.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
Nalmefene + Placebo	Pruritus	Phase 2
Nalmefene	Healthy	Phase 1

Opportunities

The primary opportunity is addressing the large, unmet need for an FDA-approved therapy for debilitating pruritus in PBC patients.

Success with TH104 could also unlock the platform's potential for reformulating other challenging drug molecules in hepatology and beyond, creating multiple pipeline candidates.

Risk Factors

Key risks include clinical trial failure of the lead candidate TH104, limited cash runway necessitating dilutive financing, competition from other late-stage therapies for pruritus, and the inherent technical and regulatory risks associated with a novel drug delivery platform.

Competitive Landscape

Competes in the symptomatic treatment of PBC pruritus against off-label therapies and recently approved drugs like Seladelpar. Differentiates through its unique buccal film delivery of nalmefene, aiming for targeted pruritus relief with potentially fewer systemic side effects compared to oral formulations.